VERZENIO 150mg Medication ( Abemaciclib 150 mg )

What is Verzenio?

Certain patients with HR+/HER2– (hormone receptor positive/human epidermal growth factor receptor 2–negative) breast cancer may benefit from treatment with the oral medication verzenio (abemaciclib). Seventy percent of cases of breast cancer are HR+, HER2-type tumours. Breast cancer can affect both sexes and occur at any age.

Instead of being a chemotherapy, This tablet is regarded as a focused medication treatment. This medication, which is taken orally twice daily, is referred to as a CDK 4 & 6 inhibitor. via preventing the proliferation of cancer cells, it functions via inhibiting cyclin-dependent kinases 4 and 6.

It can be combined with endocrine therapy (tamoxifen or an aromatase inhibitor) as an adjuvant for adult males or females with HR+/HER2-, node-positive, early

Verzenio 150mg DOSAGE AND Used

When used in combination with fulvestrant or an aromatase inhibitor, the recommended dose of VERZENIO is 150 mg taken orally twice daily.

When given with VERZENIO, refer to the Full Prescribing Information for the recommended dose of the aromatase inhibitor being used.

The recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29; and once monthly thereafter. Refer to the Full Prescribing Information for fulvestrant. Pre/perimenopausal women treated with the combination of VERZENIO plus fulvestrant should be treated with a gonadotropin-releasing hormone agonist according to current clinical practice standards.